PD-1/L1 checkpoint inhibitors
1 abstract
Abstract
Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC).Org: Ren Ji Hospital, Renji Hospital Shanghai Jiaotong University School of Medicine,